Bausch Health News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.09.23	BHC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC (PR Newswire)
03.09.23	ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
25.08.23	ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
18.08.23	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
11.08.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
04.08.23	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
28.07.23	ROSEN,TOP RANKED GLOBAL COUNSEL, Encourages Bausch Health Companies Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BHC (PR Newswire)
31.05.23	OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease (PR Newswire)
12.10.22	SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION (PR Newswire)
05.10.22	Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022 (PR Newswire)
03.10.22	SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY (PR Newswire)
28.09.22	Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations (PR Newswire)
23.09.22	Bausch Health, Glenmark Specialty Say Health Canada Approves RYALTRIS (RTTNews)
14.09.22	Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations (PR Newswire)
09.09.22	Bausch Health Comments On Tentative FDA Approval Of Generic Version Of Antibiotic Xifaxan (RTTNews)
09.09.22	Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin (PR Newswire)
08.09.22	Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations (PR Newswire)
31.08.22	Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes (PR Newswire)
22.08.22	Bausch Health Continuing Process Toward Separating Bausch + Lomb (PR Newswire)
11.08.22	Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit (PR Newswire)
10.08.22	Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE) (PR Newswire)
09.08.22	BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS (PR Newswire)
28.07.22	Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation (PR Newswire)
28.07.22	Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9 (PR Newswire)
20.07.22	Bausch + Lomb Provides Leadership Update (PR Newswire)
13.07.22	Salix Announces 2022 Gastrointestinal Health Scholars Program Winners (PR Newswire)
23.06.22	Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors (PR Newswire)
21.06.22	Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation (PR Newswire)
20.06.22	Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022 (PR Newswire)
16.06.22	Bausch Health Provides Update on Solta Medical (PR Newswire)
18.05.22	Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022 (PR Newswire)
11.05.22	Bausch Health Announces Participation In Upcoming Investor Conferences (PR Newswire)
10.05.22	Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions (PR Newswire)
10.05.22	Bausch Health Companies Inc. Announces First-Quarter 2022 Results (PR Newswire)
06.05.22	Bausch Health Announces Thomas J. Appio As Chief Executive Officer (PR Newswire)
06.05.22	Bausch + Lomb Prices IPO Of 35 Mln Shares At $18.00/shr (RTTNews)
06.05.22	Bausch + Lomb Corporation Announces Pricing of IPO (PR Newswire)
03.05.22	Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting (PR Newswire)
29.04.22	Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10 (PR Newswire)
28.04.22	Bausch + Lomb Corporation Announces Launch of IPO and Roadshow (PR Newswire)
28.04.22	Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation (PR Newswire)
28.04.22	Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting (PR Newswire)
27.04.22	Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference (PR Newswire)
25.04.22	Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting (PR Newswire)
21.04.22	Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs (PR Newswire)
20.04.22	Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health (PR Newswire)
18.04.22	Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting (PR Newswire)
04.04.22	HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR (PR Newswire)
29.03.22	Bausch Health Will Reduce Debt By $200 Million (PR Newswire)
28.03.22	Bausch + Lomb, Clearside Biomedical Launch XIPERE For Macular Edema Associated With Uveitis In U.S. (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bausch Health

Aktien Top/Flop

Meistgelesene Nachrichten